Stryker Corporation 10-Qquarter ended 2026-09-30

Executive Summary

Stryker sells surgical equipment, implants and medical technologies to hospitals, surgery centers and healthcare providers, earning revenue from product sales. It is expanding its robotics and vascular portfolios through Ortho Tech, the AVS acquisition and a planned partnership with CMR Surgical. Q3 sales reached $6.52B, with growth accelerating from the nine-month pace, but a $293M Peripheral Vascular impairment exposed a slower recovery in that business and pushed reported earnings lower. Demand across the broader portfolio supports growth; investors must judge whether new technologies and acquisitions deliver enough to offset operational constraints and acquisition-related costs.

What's Happening in the Business

Growth was concentrated in MedSurg and Neurotechnology, particularly Endoscopy and Medical. Orthopaedics grew more slowly: Ortho Tech and Trauma and Extremities advanced, while Hips declined and Knees were broadly flat. Unit volume, rather than pricing, drove nearly all Q3 sales growth, making procedure demand and product adoption more important than price increases.

Stryker created Ortho Tech in Q1, combining Orthopaedic Instruments with Mako and enabling technologies. It is also pursuing broader robotics exposure: in October, it agreed to invest ≈$400M in CMR Surgical preferred equity, obtain exclusive U.S. distribution rights for Versius and receive an exclusive option to acquire the remaining equity. Management expected closing in Q4, subject to approvals and customary conditions.

Vascular expansion came with a warning. Stryker acquired AVS in May for $434M net cash plus potential milestone payments of up to $400M; AVS is developing intravascular lithotripsy for complex peripheral arterial disease. Separately, lower forecasts, supply constraints and a longer recovery timeline triggered the Peripheral Vascular impairment, leaving ≈$3.26B of goodwill in that business.

The cybersecurity incident reported on 3/11/2026 continued to affect operations. Idle production time contributed to manufacturing costs, and management remained uncertain about its ultimate operational and financial effects.

Key Financial Highlights

• Growth drivers: Q3 Endoscopy revenue was $1.02B, +14%; Medical $1.08B, +9.7%; and Ortho Tech $754M, +16%. MedSurg benefited from volume and lower manufacturing costs; higher selling and manufacturing costs restrained Orthopaedics’ profit growth.
• Gross margin: Q3 reached 65.2%, from 63.6%, helped by volume, product mix and lower acquisition-inventory accounting costs. Nine-month results also included a $158M benefit from reversing 2025 tariffs—not recurring operating improvement.
• Costs outside segments: Q3 structural optimization and special charges rose to $153M from $41M, corporate costs reached $237M from $200M, and impairment charges rose sharply. These explain why segment profits improved while consolidated operating income fell.
• Capital allocation: Nine-month FCF was $2.70B, +12%, after $605M of capital spending. Stryker repurchased $1.00B of shares and paid $1.01B in dividends vs $963M; shares outstanding fell 0.5% from year-end, net of issuance. Total debt declined 5.9% to $14.9B following a note repayment.

Risk Assessment

• Peripheral Vascular valuation: Its reduced forecasts leave further write-down risk; management’s sensitivity analysis indicated an additional $823M impairment from a 100bp increase in the discount rate.
• Cybersecurity and supply disruption: Production downtime and vascular supply constraints can delay sales, raise costs and undermine recovery forecasts.
• Acquisition-heavy balance sheet: Tangible common equity remained negative at $(1.41)B, making acquisition performance and the durability of goodwill particularly consequential.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Peripheral Vascular recovery: Subsequent filings should show whether supply constraints ease and forecasts stabilize; further forecast reductions or impairments would signal a longer recovery.
• Robotics adoption: Ortho Tech’s current growth and the planned Versius distribution agreement broaden Stryker’s opportunity; sustained sales growth and commercialization would validate it, while delays would weaken the case.
• AVS development: Its lithotripsy platform remains in development; product progress would support the acquisition rationale, while delays would postpone its contribution.
• Production normalization: Lower downtime-related costs without lost sales would indicate recovery from the cybersecurity incident; persistent disruption would pressure margins and cash generation.